4/A: Aadi Bioscience CEO Receives Stock Grant
Insider Transaction (Form 4/A)
David James Lennon, CHIEF EXECUTIVE OFFICER and a Director of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
Summary
- Grant/award: acquired 193,957 Stock option (right to buy) on September 15, 2026; holds 193,957 after (Direct).
- Grant/award: acquired 193,957 Restricted Stock Units on September 15, 2026; holds 193,957 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David James Lennon — Director, Officer (CHIEF EXECUTIVE OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Grant/award | Stock option (right to buy) | 193,957 | — | — | 193,957 |
| 2026-09-15 | Grant/award | Restricted Stock Units | 193,957 | — | — | 193,957 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Grant/award (193,957 shares) |
| 2026-09-15 | Grant/award (193,957 shares) |
Keywords
insider transaction, Form 4/A, WHWK, Whitehawk Therapeutics, Inc., neutral, David James Lennon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.